Silverarc Capital Management, LLC Biohaven Pharmaceutical Holding CO Ltd. Transaction History

Silverarc Capital Management, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 25, 2022	SELL	$83.14 - $145.99 $6.33 Million - $11.1 Million	-76,123 Reduced 74.27%	26,374 $3.84 Million
Q1 2022 May 13, 2022	BUY	$110.08 - $142.92 $2.44 Million - $3.17 Million	22,149 Added 27.57%	102,497 $4.36 Million
Q4 2021 Feb 14, 2022	BUY	$99.73 - $148.48 $1.84 Million - $2.74 Million	18,451 Added 29.81%	80,348 $11.1 Million
Q3 2021 Nov 15, 2021	BUY	$98.85 - $138.91 $521,038 - $732,194	5,271 Added 9.31%	61,897 $8.6 Million
Q2 2021 Aug 16, 2021	BUY	$65.78 - $105.02 $430,003 - $686,515	6,537 Added 13.05%	56,626 $5.5 Million
Q1 2021 May 18, 2021	BUY	$64.07 - $91.75 $2.15 Million - $3.08 Million	33,589 Added 203.57%	50,089 $3.42 Million
Q4 2020 Feb 16, 2021	BUY	$65.07 - $98.24 $1.07 Million - $1.62 Million	16,500 New	16,500 $1.41 Million

785K

Ticker BHVN
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,645,000
Market Cap $3.65B
Description
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavege...

Get notified when there are updates to the investment portfolio of Silverarc Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Silverarc Capital Management, LLC with notifications on news.